Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cagrilintide

Peptide · developed by Novo Nordisk

Phase 3 Most advanced trial
NVO Developer
1 Registered trials

What is Cagrilintide?

Cagrilintide is a drug administered subcutaneously by pen injector as an adjunct to lifestyle intervention counselling. It is studied in overweight, obesity and type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Therapy area
Endocrine, Metabolic
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
AO43BIF1U8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07220759 Phase 3 Overweight Active not recruiting NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ObesityOverweightType 2 Diabetes

More from Novo Nordisk

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Cagrilintide

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.